Recent advances in mantle cell lymphoma: Report of the 2012 Mantle Cell Lymphoma Consortium Workshop

Michael E. Williams*, Steven H. Bernstein, Pedro Jares, Brad S. Kahl, Thomas E. Witzig, Leo I. Gordon

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma characterized by overexpression of cyclin D1 and the t(11;14)(q13;q32) chromosomal translocation. MCL is biologically and clinically heterogeneous and frequently disseminates to extranodal areas. While a subset of patients have an indolent clinical course, the overall outcome for patients with MCL remains poor. There is no proven curative therapy, and no standard of care has been established for initial or subsequent lines of therapy. Several regimens are highly active in previously untreated patients, and recent research has led to improvements in currently available therapy. Moreover, investigational agents have recently demonstrated promising activity in clinical trials. A workshop was held to review recent data on MCL pathogenesis, novel molecular targets and alternative approaches to immunotherapy, and to discuss recent and ongoing clinical trials in MCL. The presentations are summarized in this article, which is intended to highlight areas of active investigation and identify important avenues for future research.

Original languageEnglish (US)
Pages (from-to)1882-1890
Number of pages9
JournalLeukemia and Lymphoma
Issue number9
StatePublished - Sep 2013


  • Immunotherapy
  • Mantle cell lymphoma
  • Pathogenesis
  • Targeted therapies

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Recent advances in mantle cell lymphoma: Report of the 2012 Mantle Cell Lymphoma Consortium Workshop'. Together they form a unique fingerprint.

Cite this